Trade CTXR stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Citius Pharmaceuticals, Inc. (CTXR) is trading at US$0.60, up 2.06% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$16.48M. Over the past 52 weeks, CTXR has traded between US$0.47 and US$2.19. On Syfe you can trade CTXR with $0 commission and add it to your watchlist.
| Previous close | US$0.59 |
|---|---|
| Market cap | US$16.48M |
| 52-week range | US$0.47 – US$2.19 |
| Volume | 279.88K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.
Year: 2011
Citius Pharmaceuticals, Inc. (CTXR) stock is trading at US$0.60, +2.06% from the previous close of US$0.59.
The market cap for Citius Pharmaceuticals, Inc. (CTXR) stock is approximately US$16.48M.
The 52-week high for Citius Pharmaceuticals, Inc. (CTXR) stock is US$2.19.
The 52-week low for Citius Pharmaceuticals, Inc. (CTXR) stock is US$0.47.
Citius Pharmaceuticals, Inc. (CTXR) does not currently pay a dividend.
Stay on top of CTXR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
